The study also showed that, compared with chemotherapy, the improvement of nivolumab plus chemotherapy on pCR was consistent in key subgroups, including disease stage (IB/II [26.2% vs. 4.8%]; ≥IIIA [23.0% vs. 0.9%]), PD-L1 tumor proportion score (<1% [16.7% vs. 2.6%]; ≥1% [32.6% vs. 2.2%]), and tumor mutational burden (low [22.4% vs. 1.9%]); high [30.8% vs. 2.7%]) (19). Here, CD274 is linked to neoplasm.